<SEC-DOCUMENT>0001193125-11-220768.txt : 20110812
<SEC-HEADER>0001193125-11-220768.hdr.sgml : 20110812
<ACCEPTANCE-DATETIME>20110812111730
ACCESSION NUMBER:		0001193125-11-220768
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110808
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110812
DATE AS OF CHANGE:		20110812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NATURAL ALTERNATIVES INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000787253
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				841007839
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15701
		FILM NUMBER:		111029808

	BUSINESS ADDRESS:	
		STREET 1:		1185 LINDA VISTA DR
		CITY:			SAN MARCOS
		STATE:			CA
		ZIP:			92069
		BUSINESS PHONE:		6197447340

	MAIL ADDRESS:	
		STREET 1:		1185 LINDA VISTA DRIVE
		CITY:			SAN MARCOS
		STATE:			CA
		ZIP:			92069

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERICAN ACQUISITIONS INC
		DATE OF NAME CHANGE:	19860929
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>DATE OF REPORT (Date of earliest event reported): AUGUST&nbsp;8, 2011 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-15701 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission file number) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>NATURAL
ALTERNATIVES INTERNATIONAL, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>84-1007839</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State of incorporation)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer Identification No.)</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1185 Linda Vista Drive</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>San Marcos, California 92078</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(760) 744-7340</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number)</B></FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;1.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Entry into a Material Definitive Agreement. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;8, 2011, the U.S. District Court for the District of Delaware approved a settlement agreement between Natural Alternatives International, Inc. (&#147;NAI&#148;) and Vital Pharmaceutical,
Inc. (&#147;VPX&#148;). As part of the settlement, NAI granted VPX a limited and restricted covenant not to sue on certain claims of NAI&#146;s asserted beta-alanine patents and VPX agreed to dismiss its claims of invalidity and to cease certain
business activities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;9, 2011, NAI executed an Agreement to License with Compound Solutions, Inc.
(&#147;CSI&#148;) under which NAI has agreed to renew its agreement with CSI to grant a license of certain of NAI&#146;s rights to the use, manufacture and sale of products incorporating its patented Carnosyn<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> beta-alanine to customers of CSI who purchase the material beta-alanine from CSI (the &#147;CSI Agreement&#148;).
NAI will receive a license fee from CSI that will vary based on the quantity of beta-alanine sold by CSI and the source of such beta-alanine. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;12, 2011,
NAI issued a press release announcing the CSI Agreement and the settlement of its patent litigation case with VPX. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits. </FONT></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press release dated August 12, 2011 of NAI.</FONT></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Natural Alternatives International, Inc.</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: <B>August&nbsp;12, 2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Ken Wolf</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Ken Wolf</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Chief Financial Officer</B></FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g220888image02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Natural Alternatives International, Inc. Announces </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Resolution of Patent Litigation Case and Renewal of Beta-Alanine Licensing </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Agreement with Compound Solutions, Inc. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">SAN MARCOS, CALIF, August&nbsp;12, 2011 &#151; Natural Alternatives International, Inc. (&#147;NAI&#148;) (NASDAQ: NAII), a leading formulator, manufacturer and marketer of customized nutritional
supplements, today announced that it reached a settlement with one of the defendants to litigation pending before the U.S District Court for the District of Delaware, Vital Pharmaceutical, Inc. (&#147;VPX&#148;). As part of the settlement, NAI
granted VPX a limited and restricted covenant not to sue on certain claims of NAI&#146;s asserted beta-alanine patents and VPX agreed to dismiss its claims of invalidity and to cease certain business activities. Other terms of the confidential
settlement were not disclosed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;3, 2011 NAI amended its complaint originally filed in August 2009 against
the second defendant, DNP International Co., Inc. (&#147;DNP&#148;), to reassert its federal claims for unfair competition and false advertising as well as state claims for deceptive trade practices. According to the amended complaint, &#147;DNP has
repeatedly attempted to unfairly compete&#148; with NAI&#146;s CarnoSyn<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> beta-alanine product licensed to
Compound Solutions, Inc (&#147;CSI&#148;) a science and marketing based distributor of raw materials to the sports nutrition, dietary supplement, food, pharmaceutical and personal care industries. CSI is also a plaintiff in the case. NAI&#146;s
amended and supplemented claims arise from &#147;knowingly false and misleading statements made by DNP to improperly boost sales of its imported beta-alanine product.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In support of its asserted claims, NAI has also alleged that recent DNP public statements and marketing related to beta-alanine were false and misleading. Specifically, on July&nbsp;19, 2011, DNP issued a
press release regarding the status of the action originally filed by NAI. The DNP </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
press release stated that claims filed by NAI against DNP were dismissed because of the Court&#146;s earlier claim construction ruling construing certain terms of patent claims asserted by NAI.
This statement by DNP was knowingly false. The Court&#146;s June&nbsp;22 ruling on pending motions filed by NAI, CSI and DNP was not based on the Court&#146;s earlier claim construction order. DNP&#146;s press release also suggested that the Court
had affirmatively ruled that certain NAI beta-alanine patent claims were invalid. In truth, the Court did not rule that NAI&#146;s patents were invalid and any suggestion by DNP otherwise was false and misleading. NAI and CSI further allege in the
amended complaint that DNP issued the July&nbsp;19 press release after it &#147;tried to improperly coerce NAI and CSI into entering into a settlement agreement with DNP.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The complaint also alleges that, contrary to DNP&#146;s July&nbsp;25, 2011 advertising and sales statements distributed to actual and potential purchasers of beta-alanine, DNP is not the number one
importer of beta-alanine. The complaint further alleges that DNP falsely advertised in 2009 that it was the only source for Japanese beta-alanine in the United States and that it had an exclusive manufacturing facility. Contemporaneous with the
filing of its amended complaint and acceptance of the VPX settlement, NAI chose not to reassert patent claims against DNP previously dismissed by the court. Trial in the case against DNP is currently scheduled for May 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">NAI also announced today that it had renewed its agreement with CSI to license certain of NAI&#146;s rights to the use, manufacture,
and sale of products incorporating NAI&#146;s patented Carnosyn<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> beta-alanine to CSI&#146;s customers for use in
the dynamic human performance product market. CSI is an importer and distributor of bulk beta-alanine. Mark A. LeDoux, NAI&#146;s CEO and Chairman of the Board, said that &#147;NAI continues to invest in strengthening and broadening its worldwide
intellectual property portfolio directed to beta-alanine. All of NAI&#146;s issued patents remain valid and NAI remains committed to continue to develop, license and enforce its beta-alanine intellectual property rights. Given the significant
investment by our company in its intellectual property portfolio related to beta-alanine and the importance of this business, both to NAI and our business partner, CSI, we will aggressively address false and misleading statements made by market
competitors. NAI will not stand by and allow third-parties to intentionally mislead current and future customers of
CarnoSyn<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> beta-alanine licensed by NAI and confuse the general marketplace regarding NAI&#146;s intellectual
property. &#148; </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of
nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical
studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration
assistance. For more information about NAI, please see our website at http://www.nai-online.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains forward-looking
statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations
and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish
to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI&#146;s financial performance
and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on
Form 10-K and Quarterly Report on Form 10-Q. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTACT - Kenneth Wolf, Chief Operating and Chief Financial Officer, Natural Alternatives
International, Inc., at 760-736-7700 or investor@nai-online.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Web site: http://www.nai-online.com </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g220888image02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g220888image02.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````4```_^X`#D%D
M;V)E`&3``````?_;`(0``@("`@("`@("`@,"`@(#!`,"`@,$!00$!`0$!08%
M!04%!04&!@<'"`<'!@D)"@H)"0P,#`P,#`P,#`P,#`P,#`$#`P,%!`4)!@8)
M#0L)"PT/#@X.#@\/#`P,#`P/#PP,#`P,#`\,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,_\``$0@`8@!4`P$1``(1`0,1`?_$`+````,``P$!`0``````
M```````&!P0%"`()`P$``@,!`0$!``````````````8$!0<"`P$($``!!`(!
M`@0#!`@#"0`````!`@,$!1$&`"$2,1,4!T$B%5%A,A9Q@6(C,V,T"$)2<Y&Q
MX=(U=;47-Q$``0,"!`,%!`8'!P4``````1$"`P`$(3$2!4%1!F%Q@2(3D3(4
M%:'!0E)B<O"QDB,S0P?1X?&"LE,D<S2T-1;_V@`,`P$``A$#$0`_`/OYPHHX
M44<**Y@]V_\`VQI>QS=QT?86F]7NXC#=U$M(LFRC5TR.0TAUJ-%2MY*7T%(5
MV`)2I)4KJKGT4P[9\)<1B*9OG:2B$-+@<4).&';CCV5%-0_N@W_7I&R4_N&W
M4[AL")C1UF#1(=3ZJ&Z%%3Z1&1,(2V00ONP6^TE>"0GG6FK:ZZ>MY0UT&IC4
M\Q=P/+'3X<UPIEA?W:7C4)Z3LNFHH(3L5+K6P2V9T6+%=?:>=8;D!;#@`4EK
M*5*6D'!3@'&?FFH[^FHRY(WZBN00DHBIB.?(\Z3]-]SO[F=XA^BB;!KZYM^7
MS4PH=>X9L:&XZ0S)?E(\V*PL,D.E#I2H$]@3G'!!4JZV_;+9REKD:BDG`GB`
M,'''!0HXUWOJ].]KVNTE'(L7[B35PV8TFUE+4MZ0XA("W5J4225*R>IYS29<
M2B61SP``2J#AV5ON%>-'"BCA11PHHX44<**.%%<A^\FJU4N594^BT4M>S^F?
M>LH,.06(+PE-9=9<C'*%=Z$A3A'8G!`*BI83SH4S[5<O:`Z9PT*$)"D(<U[.
M&?=A2$Y'O;7<YZ[.#+F:O`JM:BW3L&2(KB2N$V41$NX/RK>5E*<)'><]Z5$<
M*FAT;(1I(#R7D*%XY^SOPX5VKJE7K]92PSK<-,6NL&T34.85YKWGI"PXZI>5
MJ40>I4<_#G-*5S)(]Y]0J1A[.5,G"O"CA11PHHX44<**PY5A"@KB-2Y3<=R>
M\(\)"U8+KI!(0D?$X!Y%N+V"W<QLKPTO=I:"?>=F@[<*]&1.>"6A4"GL%2N'
M[AM2KC;H+U]7UKT6:*O6Z^2,DO-_(MY7;\R@M9Z`?9S.+7KALUY>PNN(XW-D
M]*%C_O-\I>4\S@Y^0[*N9-K+8XG!CG`C4XCER\!6YT_1[*BL)ES?[-+V*TEY
M"`M2T1V@K\7:UW%.3X9QT'+?I?I&YVVX?=7MT^XE=DI(8U<T8I"^&`R%>%_N
M+)V".*,,:/:?&D7W;KW85Q46U+,=JK*0U)F6,M)REQN`AMM*486VM*U>>G*@
ML)#:5*7GM''L5Z[8\.8YKPHP`_S+WX8<E4A,ZY<]G9=YM\W8&]HB3-2LH=M4
MPIU2S9HM8LN*I*$U\ZO=[,I>+;R5@.ESY$J6DA2,\^FF'=&L@:WTR'`M<04T
MD'[37#DHX)C@<Z^A$G7X+]`-<;4]$@MQ41(RV'5H=:0TD);*7`>[*0!XG]/*
M_<[!E_;/@>7-#@BM):X<B".(_P`:2H[AS)?4P)5<1@?"I[4LS/;J._`V;?&)
M-?8)<%')L`H/M.I'^914%``@D$\S_;8YNE8W0[AN#71R`^DZ0'6UP[27`C$$
M@G/*K:=S=P(=#"0X>\&Y$5O-(W-FZUFJL+>;';G2I3E:700A$B2TI206Q^V$
M]P'+CI+JIFX;9#-<R-$CGF)<@][20-/Y@-0%1MQL##.YK`4`U=P//NJA<=JJ
MZ.%%>5K2VA;BCA*`5*/W#J><O<&M).0KZ`I2HM>2KO;DZ!N&IUS,EF*[+>$.
MP>0PGO6`TWDYR3\JB.WF4;O<7N^C;=TVV(.:TR.TR.#`I1C>*DX.(2K^W9%:
M^M!.X@E`K0O:?JI^UREF,L&;L<.J5>NNJ<\Z#'2@-(5@I;#BAW*(.<JZ9XZ;
M%M4S&>M?,A-P22L;`-(X-U'S.(Q\V"U6W=PTG3$7:.TY]J4V\9:@U)_>>GL+
MC3'$UM=)LWH$MB8[&KR4SO+:))5%4DI7WI.%$((4I(*1U//HJRVJ5L<WF("@
MC'+Q[._`9UR9_;1`V%[=;"6TFRO&8EF\Y;;#94Z*MIN(_"CNQT/%(;;>GI\W
MRRI+8=2@8=5@@<^FF7?WQB$#!J@(`[5BI5.(9@N:+E7T+YS216-*APYS7DS8
MK,MD]?*>0EQ/^Q0(Y'N+6&Y;HE8U[>3@"/IKMDCF%6D@]E139->WM\Q*=F#2
MNU#-Q&GU\^&4PWVTLN!01Y*B$J4$#&0>N.9/ONR;[)HM6QP&$3LD8YB1/:&N
M5-!\I<&\0<4I@M+JT:LA+]1:00?,"HY\EJK5>P1;2TOJEEMQN3K[S3,HKQA?
MFMAQ*D8^&#CKS1]OWJ*]NKBV:"'0.:UR\=3=0(JEFM711L><G@D>!2M]RYJ-
M2=MFQF@=UUER.V["OK)-=-><)`:2ZA7:H?#JK`Z\5NI=]^6/MF.:"R>41.)^
MR'`H?;AC4^RM/7#R#BUNH=J5.M$U+6$W+\5K8)FS.:@ZE<..2170W75+4`UV
MDA:T_')Z<1^CNF=L%XZ-MR^X-J06C^1$YQ)\B$ASV\<<.^K7<KZ?TP2P,]3,
M_;<!SY`U;438;KRXS<MER0WGS(Z7$E:<>.4@Y&.:TRZA>\QM>TN&8!"CPSI>
M,;@%(*5YD6$"(L-RIK$9:D]P0ZXE!(\,X41TYS->P0%))&M.:$@?K-#8GNQ:
M"?"LI*@H!22%)4,I4.H(/Q')`((495QE4S]L-%?T2OOHC\QJ8NXMG+!:VEN+
M!66FV2H^9U22&A\B?E3C`Y]U`Y58;C>"Y<T@(C4_6?KSXU1WY#$9LNR7VX[0
M."XXH(3D^'4D#GE-/'"W5(X-',D`?34%K2XH`M87UJG\/JT//^NW_P`W(OS6
MS_WH_P!IO]M>GP\GW3[#6JVRBJM@IW$V0?"((,R',AJ*9#+C:20XR4^*L9P/
MCRLZEV>TW2S(GU(SSM<PG6US0?,Q.*<.->UC<R02>1,<"#D>PU*M8M*[6FZR
M9479V^5O]Y'8>ERSV2FVDM=JPXD$_.W@#KCQYG.P;C;[0V*6VG^*??7#&ES\
M)&M#4=J"GS,PS3.KJ\A?<ES7L],1,)09$KP[#5]YM%+-0O?M@IU3]DU7>AZ>
MD])&L]<D,`AYTM8#K:%=?G*\@?=S'^L][LS<76W;QY8-#)87-]YQ;[S0<M9<
MH'X5ICVRUD#(YK;%ZEKER"Y'N2G_`-O8+<+4ZKLI&=?5*;+ZZYHJ44]Y)25J
M7E144X)SQTZ(M&V^TPI`V`N&HL"E%R+B<2XM15_NJLW20ON'*\O3!:6=QB.5
M-TULU7%3ZBO*)$E+2<*>SW)=;5CQ\QL$#]H)^)XO]46SK&]&X6S/-&CG(,7Y
MA[3SUL4?G:WB:F6#Q+$87G`X#LY'P/T$TRWU;4[-&H)X0U(8D28ZDOE"5>;&
M<_>%LG[%8!Y?;S86F\16TR-<USV%4!U1GS:>XX5$MI9+9SVX@@'P.2TV2GVX
M,-^00`W%:4L('082.@'^[C-<S-MH7/X-!/L&506-+W`<S4]]NYLCOO:N:MQ4
M@2$V;0>_B!$X%3B"/Y;R5I/$?H:[D6XMI2=6H2C5[R38N;_DD#VFK3=8PC'M
MR33A^'+VA*HS\>/*;4S)8;D,J_$TZD+2?T@@CCW-!',W1(T.;R(!'L-537EI
M4%#41JZ"E;]P:%":R-VIJK<!);203&GAEE1!&"4MGM!/7F2[=LMDW?[<"%F$
M,_`?RYM##VEK?*N=,,US*;-_F/O,^EJGZ:N8``````&`!X`<UX``(*7*YQM)
M.GZ?O%_;VM0FGMZZ.Y,UWRNY4>Q\YL#N[#\J74KR/EQTZ^(YA>XS[/L6^7%S
M<0B*:-I?"BZ)]814R$@<H\J#%<Q37"RYN[5C&.U-)1W-J'_2E5CZELWY!^K^
MG9_,_P!+]7Z7L/E^=V=_9VYSG'3Q\>:1\?N7R'XK2WXKT=>E,-2:D1<TPSSJ
ME]&#XOTU/IZD7LRJ5;KM!BRK6GV:D1.V>!(+WM[+;8[FW1('8V2#D%31.2#D
M$CF<=6=0^C+-:[A`'W;':K1P:K7!^#3Q!+#B05!(&"BKG;[/4ULD+TC(20+B
M$S]M7VJ1,15UR+%T/STQFA->``"G>P=Y`3TZG/AS9]M;,VUB$YU2!C=1YN0:
MCAAG2U.6F1V@(U2G=6%+B(G2;&(L]H?B-I"QXI5W**5#[P<'D2YMA<R2Q'[3
M!X%2A\#C7HQ^AK7<C4ZU:<[`EG49@#2H4Y$JI1_)4M0>:'^DX<C]E0XC=.7;
MK67Y9+@62!\?Y23K8/R/R_`YO"K2]C$C?7;Q"'OX'Q'T@TY;C9(@PH3*XLJ:
MF;+:3(C0F%2'2PV?,</EHZX.`DGX9XU=4WXMH(V%CWA[VJUC2]VAOF=Y1BF`
M:3PU"H%A$7N)4!`<24"G`8_3X4AU]NTG=X=DU"G5T2R==KG&9T=<99]4GU#:
M@ESJ0'FW!D?%7$VQW-HWQEPV.2-DA=$1(PQG]X/4:4=F/4:\+S>E6<L!^%+"
M02T!V!7+RG+\)'LJU\UFEZI%7_\`T.C_`.UWW_DT\S.P_P#?P?\`2N?_`"*O
M)?\`LW_FC_T57>:95'4-WVYKZ3;H;NX0A9ZTJ(F31X9"U,6,915V!0&3YH^!
M./#F0]9;I;[?N[';G'ZEKH#HO*I9.PJBC'SC@3IRY&F+;+=\UN1`=,BH['-A
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MR7.WU#:B5I*^W&"%#!S@X/(,.\$[P^`M=H+``[2Y-;3B%1$0C250H:]76W_&
M#E"KDHR-86QT;:MFU>Z0A:5(GI#KK8)[5^6M/S8_PK3\I^\)Y$WW:&G<[2[`
M/\0*1P.DC'\+F^4]K65Z6ER?0DC_``_7]1_6:R8FPQ)FY28"SV>FB%JM4H']
MXX'")&.G3!2D8/CC(Y[VN]PW&\OA.&EB,_$[4?4[LFYY@**X?:N9;!W,X^SR
M_72G[K6\&''1Y*ENW<%*)$5AI"UJ#C;K;C/@"!D@_JSQ;_J/N4$$8TDF=@#F
M@`DZFN:YF0YKX+4[98'O./N'`^((-4:#LM5-HX]^9'IX+R$J<4X%`MJ/BA0(
MSD'IX<>K/?K6XL6WNK3&0%5?*>+2$50<*J9+21DIB12*CM=M=*=\I)1>=1$1
M7VK+LM3+@;0Y+F^H:2I13T)0G]1Z<S"PZDLOGL$A<0STYP7%K@T&27U&`E.+
M1X$@5?2V4OPCP@74PHH^RU#]-.5IMMI&V%N!'*/3K6V&(_9W%Q"^SM)/XCYG
M<<%/1./FXS[CU-=0[B(6)I):@1=0*(>9UJ4+<&IYN-0(;&-T.HYXX_IR[<^%
M(VUWT35?<.98W%6Y=UES71GJ)AM(>S-B**4^6.H!'<>OW\4NI-XAV;J%\]U"
M9HIHF.B`&K][&4&G@#B<>"U8V5LZYLPR-VES7$.X>5W.F_ZE[F?E#Z[Z&)];
M];ZS\O\`9\WT[&?3YSGS,=?M^'CTXS?']3?*/C/39Z_J:_13'T/]O\_'GPSP
MJ#Z-C\3Z:G0B:OQ\^ZMEO6T?EMV`JVUI=QJSXS86+20ZJ,ZE0*"IHC&.F<Y'
M)W6'4/RET9N;4RVCO?>!J]-P*M5IX<5PKQVVS^(!T2:9!D,E'?2)IFX5!V/W
M)VUR<6M6<<KTMSG$K[?,*2@?+C(/7!Z<3^E>I[3YENFYND(M"8D<04U(6Y(H
M[<*LK^QD]&"`#]YYL*O[;B'6T.MJ"VW$A3:QU!21D$?IYM+'M>T.:5!"@]E+
M)!!0UHK;9(-3*C5Y8E6-K-07(U7!9+SQ;20DN+/1#:`H@=[BDIS\>=5[10.>
M"[``<3^F)[!2#,]XM:IE/N;+46^NPHI5ZVZ=CMS8,8)."N5*K79;<<?>\4<^
M:!FE3&[7+)A&YKB<@J$]P<&D^"U^R/=C7;:L=O=4]-LE`TZ8_P"9!,CL0'7D
M_B99=45+<6/#Y48ST[NAP:`<Q7P[;)&[1(K7?=0ER<R.'MK.@>ZNE3R6Q*D1
M@CM]4X_$>0RR5*"/WCW9Y8'>>WN[NW/QX:!DE<OVZ=O`'Q"GPSJCA+:@"$I4
MDC((`((Y\T#E4!32KL=Q`;3-H&)"3LDVJF/U4-()<4$-J`(('3KX=>+>^[G`
MP26;'#XI\,CHVH=6#3QX8Y8X\*FVD#RDI'[L.`)\:AVE>X4&/K6KT5/0/;+N
M<!MQA#/EX1'#CI*U*?(/:",9Q^L\R3I7K:"+;;2SM;9UQ?,#F@(@9J<227I@
M"$5/$BF+<-K>Z>221X9$4/>@Y5TQW/>G[_+'J/+SY/=T[\?A[OLSTSS?-3_3
M5/,F2\4R7OXTHH%[*]N(2XVM"T)<2H$*;4,A0/P(/.WM#FD$*#P.1KX"AKF/
M:=K]+1;/K=I[=2=?L;I"TB5";2Y%=<2`&W.]*4@D`#J.?G[J'J/T+&ZL;C;'
M02S`^9@#HW.'NN4`+X+3?9V6J6.5DX>UO`E".8IRH-XD4-3[90;2('*W8(:8
MCMP5D%F0C"&T*21\1@$D\:-DZNDVVSVJ&X8L4\889%]UXP:TCV`GOY5`N=N$
M\EPYA\S"NGF.--6TZS5[LS<1ZO9)%-?-15UDJPK'PI325GO#<E@DH<2#GHH9
MP5`$9/-2M[Z"=[V1O:YS"C@""6GDX<#WU6V\S[;27L5I*@$9]H/Z<*E,[V"9
MNFFV[.)61YZ64LIV./+L`^R4=O:XQ&CJB-)62D=>[I]_):U8LWHQGRDI]TAJ
M>).HTHO?VNV%1<N[%KVU"WN7"DMVD]V136;*PCRRI$ZH*&E`C.0N(5*_QK5D
M\-521U"V1GIO8C>01[?V7X^QW<*8M?\`9;=G;2!(V[>9,36:J,\T:&$:U;LI
M$A!0\R_-;JHCX9(4<CS"I1ZD@C/.7.#0IKPFW:`-(BC!>2,3JP3(ANMP7PJO
M;/O=?KM14+H&V+V3;2D5])#CN@MK*2$J^=/=T1X?IXD=2=:0[=;126@;/),\
M,C:UV#BJ.Q"Y9=Y%0K/;7SR.$BM#0KB14NM]I.M>[=Y:V%5+M^RLCPX$>$V7
M"A;B&UJ2%'I\3GF<[GU#\HZMN+F:%\J1,8T,"H7-:2%_:]M7,%G\1M[&-<&^
M8DKWFJUH#K\FND2'=-:TYCS.RNB@)#SC.,]SB0E)2<_`\TGHM[Y;=SW6(M&J
MC&X:G-YN"`C'G5)N8#7@"7U#Q/`'LI^XZ564<**UUNQ82JR;'JIB:^Q=:*8<
MU:/,2VY\%%)\>0=SAN)K:1EL\1RD>5Q&H-/-*]8',:\%X5JXCG7-V]4WN(_7
M1$;C>Z_%IX,MMUBR(4UW/C)2/E0594,_#F$=8;5U%+;L&Z7%LV%CP0_%JOQ3
M)JJ<>"4V;;<6;7DP,>7$99X>VO#^W:]7>Y]'=ZU;,R&-C2B)MC#(7Y7FJ(2'
M`2$@G)!S]Q^WG$W4VWVG4]O=V$P<V<!EP&KIU%!JQ`XH>\$\:^ML9I+%\<S2
M"S%BYIRKI5JVJWICU>S8QW9T8!3\1+B2X@$XRI(.1S>H]SM9)G0-E:9&YM!&
MH=XI2,$@:'%I0\4K+?D,1FEOR7D,,MI*G'7%!*4@>))/0<DS31PM+Y'!K1B2
M2@'B:X:TN*`*:B?O-MS474HD2HLVL;'(],Y,97W@1DC+Q"D9^T`_IYD_]4^I
MF0[2R.VE;_R':2YI7]V/?Q'@#Q0FF#8+$NN"Y[3Y`J'GPI"FLU=I/T2'[;W]
M.J5K3"OI\&47`Z]*4>]:^Q2.TGY2KJ>)MW#;7D^WQ[%<0E]NTZ&OU!SY#YG.
M0M1<-6)SJSC=)$R9UVQR/.)"(!ES\*MNIP?<)$UZ9N%M7NQEM=C-7!:QVKR/
MG4X0/@,?'FM=-6?4#9G2[I-&6EJ!D;>/WBY!]=+U[)9EH;`URKF3]54'CK57
M1PHHX44<**Q)L"%91UP["(S.BN?Q([Z$N(./#*5`CD:[LX+N,Q3L:]AS#@"/
M8:[CE=&[4TD'F*T/Y/HXL6:U1UL.AF2V5-(L8D9H.-E0P%#H,D>(Y3?_`"]C
M#%(VSBC@>YI`>QC=35XC#,<*D_'2N<#(XO`.1)QKFZP]J=@I+FJKJY3UXF8\
MY/L;5M"F^Q+8PA+BRKJ<]0,Y)YA%[_3G<-NO(8(-4VLF1[P"U`WW0YRYJI`5
M23E39%O4,T;GO1J``#//E2/4UFY75):3DL3K7Z-8->:TLK<*5$*\\%!/S#`'
M<.*&W;?O&X64TP;)+Z4@4%7(<=?E.8RU#VU8S36T,K6J&ZFGL[O[JZ4T/VR5
MJ_U1$VQ;M*>U!4FB=8"FFRHY!RLDY"?E.!U^/-ZZ.Z`.S^J)I1+#+_*+5:U?
MS+B!Y3ACQR%*>Y;O\3ITMTN;]I<:?Z_5=:J9`EUE#`@2@"D2(\=MM8!\0%)`
M/'2RZ<VRQD]6WMXV/YM8UI]H%5<M[/*-+WN([2:W_+JHU'"BCA11PHHX44<*
M*.%%'"BES6?Z:S_H?^JS?Z'\/\4_Q?YG^;E#T_\`PI?X?\:3^'E[Q][\?WJE
;WGO-S]UN?=P[.5,?+ZHE'"BCA11PHHX45__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
